4/A: Amicus Therapeutics CEO Bradley Campbell Corrects Form 4 Filing Regarding Stock Transactions

Amicus Therapeutics CEO Bradley Campbell amended a previous Form 4 filing to accurately reflect stock acquisitions related to a performance-based restricted stock unit (PRSU) award and to correct holdings after tax withholdings.

Summary

• Bradley Campbell, CEO of Amicus Therapeutics, filed an amended Form 4 with the SEC.
• The amendment corrects a previous filing from January 11, 2024, which inadvertently excluded the acquisition of shares granted for achieving the TSR portion of the 2021 PRSU award.
• The original filing also incorrectly reported holdings following shares being withheld for taxes.
• The corrected filing shows the acquisition of 28,810 shares on January 9, 2024, related to the PRSU award, at a price of $0.00.
• It also reflects the disposal of 23,577 shares on the same date at $13.65 per share, presumably for tax purposes.
• Following these transactions, Campbell's direct holdings are 904,196 shares of common stock.

Sentiment

Score: 7

Explanation: The document is a routine correction of a regulatory filing. While it doesn't indicate positive or negative performance, accurate reporting is crucial for investor confidence.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• Accurate reporting of insider transactions ensures transparency for shareholders.

Key Dates